Shouyao Holdings (Beijing) Co. Ltd. A
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of innovative drugs in China. The company offers drugs for various indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, … Read more
Shouyao Holdings (Beijing) Co. Ltd. A (688197) - Net Assets
Latest net assets as of June 2025: CN¥704.64 Million CNY
Based on the latest financial reports, Shouyao Holdings (Beijing) Co. Ltd. A (688197) has net assets worth CN¥704.64 Million CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥819.45 Million) and total liabilities (CN¥114.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥704.64 Million |
| % of Total Assets | 85.99% |
| Annual Growth Rate | 35.88% |
| 5-Year Change | 452.52% |
| 10-Year Change | N/A |
| Growth Volatility | 32112.38 |
Shouyao Holdings (Beijing) Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Shouyao Holdings (Beijing) Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shouyao Holdings (Beijing) Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Shouyao Holdings (Beijing) Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥809.01 Million | -20.76% |
| 2023-12-31 | CN¥1.02 Billion | -15.38% |
| 2022-12-31 | CN¥1.21 Billion | +80243.11% |
| 2021-12-31 | CN¥1.50 Million | -98.97% |
| 2020-12-31 | CN¥146.42 Million | -16.12% |
| 2019-12-31 | CN¥174.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shouyao Holdings (Beijing) Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 94227346433.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.83 Billion | 225.80% |
| Total Equity | CN¥809.01 Million | 100.00% |
Shouyao Holdings (Beijing) Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shouyao Holdings (Beijing) Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Jiuri New Materials Co Ltd
SHG:688199
|
$278.88 Million |
|
Xinlong Holding Group Co Ltd
SHE:000955
|
$279.03 Million |
|
Wanma Technology Co Ltd
SHE:300698
|
$279.07 Million |
|
Bénéteau S.A
OTCGREY:BTEAF
|
$279.12 Million |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
$278.82 Million |
|
Primis Financial Corp
NASDAQ:FRST
|
$278.81 Million |
|
Takara Bio Inc
F:TF2
|
$278.76 Million |
|
APG SGA SA
SW:APGN
|
$278.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shouyao Holdings (Beijing) Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,020,952,158 to 809,013,113, a change of -211,939,045 (-20.8%).
- Net loss of 211,939,045 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-211.94 Million | -26.2% |
| Total Change | CN¥- | -20.76% |
Book Value vs Market Value Analysis
This analysis compares Shouyao Holdings (Beijing) Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.13x to 6.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥1.56 | CN¥37.61 | x |
| 2020-12-31 | CN¥1.31 | CN¥37.61 | x |
| 2021-12-31 | CN¥0.01 | CN¥37.61 | x |
| 2022-12-31 | CN¥8.11 | CN¥37.61 | x |
| 2023-12-31 | CN¥6.86 | CN¥37.61 | x |
| 2024-12-31 | CN¥5.44 | CN¥37.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shouyao Holdings (Beijing) Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5376.40%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-26.20%) is above the historical average (-1659.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -22.78% | -343.00% | 0.05x | 1.26x | CN¥-56.99 Million |
| 2020 | -225.46% | -4703.18% | 0.04x | 1.24x | CN¥-344.76 Million |
| 2021 | -9650.40% | -1112.00% | 0.22x | 38.74x | CN¥-145.07 Million |
| 2022 | -14.41% | -9512.74% | 0.00x | 1.08x | CN¥-294.47 Million |
| 2023 | -18.18% | -3548.79% | 0.00x | 1.09x | CN¥-287.67 Million |
| 2024 | -26.20% | -5376.40% | 0.00x | 1.14x | CN¥-292.84 Million |
Industry Comparison
This section compares Shouyao Holdings (Beijing) Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shouyao Holdings (Beijing) Co. Ltd. A (688197) | CN¥704.64 Million | -22.78% | 0.16x | $278.86 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |